{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:39:31Z","timestamp":1789389571279,"version":"build-2803163510"},"reference-count":33,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3,1]]},"DOI":"10.1210\/jc.2009-0233","type":"journal-article","created":{"date-parts":[[2010,1,9]],"date-time":"2010-01-09T02:49:36Z","timestamp":1263005376000},"page":"1279-1287","source":"Crossref","is-referenced-by-count":85,"title":["Parathyroid Hormone-Related Protein for the Treatment of Postmenopausal Osteoporosis: Defining the Maximal Tolerable Dose"],"prefix":"10.1210","volume":"95","author":[{"given":"Mara J.","family":"Horwitz","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism (M.J.H., M.B.T., A.G.-O., L.P., A.F.S.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Tedesco","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (M.J.H., M.B.T., A.G.-O., L.P., A.F.S.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Garcia-Ocan\u0303a","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (M.J.H., M.B.T., A.G.-O., L.P., A.F.S.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Sereika","sequence":"additional","affiliation":[{"name":"The Graduate School of Public Health (S.M.S.), University of Pittsburgh, Pittsburgh Pennsylvania 15261"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Prebehala","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (M.J.H., M.B.T., A.G.-O., L.P., A.F.S.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bisello","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Chemical Biology (A.B.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce W.","family":"Hollis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (B.W.H.), The Medical University of South Carolina, Charleston, South Carolina 29425"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caren M.","family":"Gundberg","sequence":"additional","affiliation":[{"name":"Department of Orthopedics (C.M.G.), Yale University School of Medicine, New Haven, Connecticut 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism (M.J.H., M.B.T., A.G.-O., L.P., A.F.S.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113491870300_R1","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113491870300_R2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113491870300_R3","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113491870300_R4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Int Med"},{"key":"key\n\t\t\t\t2019041113491870300_R5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomized clinical trial of the effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113491870300_R6","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113491870300_R7","first-page":"620","article-title":"A randomized controlled clinical trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis","volume":"82","author":"Hodsman","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113491870300_R8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1152\/physrev.1996.76.1.127","article-title":"Defining the physiologic roles of parathyroid hormone-related protein in normal physiology","volume":"76","author":"Philbrick","year":"1996","journal-title":"Physiol Rev"},{"key":"key\n\t\t\t\t2019041113491870300_R9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1056\/NEJM200001203420306","article-title":"The physiology of parathyroid hormone-related protein","volume":"342","author":"Strewler","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113491870300_R10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/dbio.1996.0104","article-title":"Haploinsufficiency of parathyroid hormone-related peptide results in abnormal postnatal bone development","volume":"175","author":"Amizuka","year":"1996","journal-title":"Dev Biol"},{"key":"key\n\t\t\t\t2019041113491870300_R11","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1172\/JCI24918","article-title":"Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH (1-34)","volume":"115","author":"Miao","year":"2005","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019041113491870300_R12","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1210\/en.2003-1695","article-title":"Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice","volume":"145","author":"Miao","year":"2004","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019041113491870300_R13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1101\/gad.8.3.277","article-title":"Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene","volume":"8","author":"Karaplis","year":"1994","journal-title":"Genes Dev"},{"key":"key\n\t\t\t\t2019041113491870300_R14","first-page":"900","article-title":"Parathyroid hormone-related protein(1-36) is biologically active when administered subcutaneously to humans","volume":"82","author":"Henry","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113491870300_R15","first-page":"2786","article-title":"Dissociation of bone formation from resorption during two-week treatment with hPTHrP(1-36) in humans: potential as an anabolic therapy for osteoporosis","volume":"83","author":"Plotkin","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113491870300_R16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1210\/jc.2002-021122","article-title":"Short-term, high-dose PTHrP as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis","volume":"88","author":"Horwitz","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113491870300_R17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00198-005-1976-3","article-title":"Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study","volume":"17","author":"Horwitz","year":"2006","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113491870300_R18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1172\/JCI113358","article-title":"A synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats","volume":"81","author":"Stewart","year":"1988","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019041113491870300_R19","first-page":"199","article-title":"Parathyroid hormone-related protein(1-36) is equipotent with parathyroid hormone(1-34) in humans","volume":"81","author":"Everhart-Caye","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113491870300_R20","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1359\/jbmr.2000.15.8.1517","article-title":"Six month daily administration of PTH and PTHrP peptides to adult ovariectomized rats markedly enhances bone mass and biomechanics: a comparison of human PTH(1-34), PTHrP(1-36) and SDZ-PTH-893","volume":"15","author":"Stewart","year":"2000","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113491870300_R21","first-page":"1525","article-title":"Parathyroid hormone-related protein (1-36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy","volume":"86","author":"Syed","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113491870300_R22","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1210\/jc.2002-020773","article-title":"Direct comparison of sustained infusion of hPTHrP(1-36) versus hPTH(1-34) on serum calcium, plasma 1,25(OH)2 vitamin D concentrations and fractional calcium excretion in healthy human volunteers","volume":"88","author":"Horwitz","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113491870300_R23","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1359\/JBMR.050602","article-title":"Continuous infusion of parathyroid hormone versus parathyroid hormone-related protein in humans: discordant effects on 1,25(OH)2 vitamin D and prolonged suppression of bone formation","volume":"20","author":"Horwitz","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113491870300_R24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/clinchem\/42.4.586","article-title":"Quantification of circulating 1,25(OH)2D by RIA with an 125-I-labled tracer","volume":"42","author":"Hollis","year":"1996","journal-title":"Clin Chem"},{"key":"key\n\t\t\t\t2019041113491870300_R25","first-page":"3258","article-title":"Vitamin K status and bone health: an analysis of methods for the determination of \u201cundercarboxylated\u201d osteocalcin","volume":"83","author":"Gundberg","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113491870300_R26","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.bone.2007.01.008","article-title":"A cross-sectional study of bone turnover markers in healthy premenopausal women","volume":"40","author":"de Papp","year":"2007","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041113491870300_R27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1359\/jbmr.080703","article-title":"Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium and the United States","volume":"24","author":"Glover","year":"2009","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113491870300_R28","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJM198012113032401","article-title":"Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and non-humoral groups","volume":"303","author":"Stewart","year":"1980","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113491870300_R29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1210\/jcem-55-2-219","article-title":"Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity","volume":"55","author":"Stewart","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113491870300_R30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1210\/me.2007-0274","article-title":"Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH\/PTHrP receptor","volume":"22","author":"Dean","year":"2008","journal-title":"Mol Endocrinol"},{"key":"key\n\t\t\t\t2019041113491870300_R31","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00198-007-0336-x","article-title":"Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis","volume":"18","author":"Sellmeyer","year":"2007","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113491870300_R32","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1359\/jbmr.080318","article-title":"Exogenous PTH and endogenous 1,25-dihydroxyvitamin D are complimentary in inducing an anabolic effect on bone","volume":"23","author":"Samadfam","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"key\n\t\t\t\t2019041113491870300_R33","first-page":"S210","article-title":"Changes in 25-hydroxy- and 1,25-dihydroxy-vitamin D during treatment with teriparatide","volume":"22","author":"Cosman","year":"2007","journal-title":"J Bone Miner Res"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/95\/3\/1279\/9067473\/jcem1279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T15:51:19Z","timestamp":1590508279000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/95\/3\/1279\/2597202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,1]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2009-0233","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,1]]}}}